Urogen Pharma (NASDAQ:URGN) Receives $33.00 Average Target Price from Analysts

Shares of Urogen Pharma (NASDAQ:URGN) have been assigned an average recommendation of “Moderate Buy” from the nine brokerages that are currently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price objective among analysts that have issued ratings on the stock in the last year is $33.00.

URGN has been the subject of several research reports. Wall Street Zen upgraded Urogen Pharma from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $40.00 price objective on shares of Urogen Pharma in a report on Monday, October 27th. D. Boral Capital reissued a “buy” rating and set a $33.00 target price on shares of Urogen Pharma in a report on Monday, January 5th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Urogen Pharma in a research report on Wednesday, October 8th.

Insider Transactions at Urogen Pharma

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of Urogen Pharma stock in a transaction dated Wednesday, November 19th. The stock was sold at an average price of $25.00, for a total transaction of $250,000.00. Following the transaction, the insider directly owned 139,025 shares of the company’s stock, valued at approximately $3,475,625. The trade was a 6.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 4.70% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Urogen Pharma

A number of hedge funds have recently made changes to their positions in the stock. Osaic Holdings Inc. boosted its holdings in Urogen Pharma by 491.2% in the second quarter. Osaic Holdings Inc. now owns 3,695 shares of the company’s stock valued at $50,000 after acquiring an additional 3,070 shares during the last quarter. State of Wyoming bought a new position in Urogen Pharma during the 3rd quarter worth approximately $66,000. Russell Investments Group Ltd. boosted its stake in shares of Urogen Pharma by 1,594.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 3,321 shares of the company’s stock valued at $66,000 after purchasing an additional 3,125 shares during the last quarter. Strs Ohio bought a new stake in shares of Urogen Pharma in the 3rd quarter valued at $76,000. Finally, CWM LLC increased its position in shares of Urogen Pharma by 18.0% during the third quarter. CWM LLC now owns 4,271 shares of the company’s stock worth $85,000 after buying an additional 650 shares during the period. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Price Performance

Shares of Urogen Pharma stock opened at $21.45 on Friday. The company’s 50 day moving average price is $23.76 and its two-hundred day moving average price is $19.93. The firm has a market capitalization of $1.00 billion, a P/E ratio of -6.20 and a beta of 1.29. Urogen Pharma has a fifty-two week low of $3.42 and a fifty-two week high of $30.00.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.69) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.72) by $0.03. The company had revenue of $27.48 million for the quarter, compared to analyst estimates of $34.09 million. On average, analysts expect that Urogen Pharma will post -3.12 earnings per share for the current year.

About Urogen Pharma

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.